Medication info

Anapher jeyjeong 5/160/20 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Amlodipine Besylate›Strength being verifiedValsartan›Strength being verifiedAtorvastatin Calcium Hydrate›Strength being verified
Manufacturer / importer
Aju Pharmaceutical Co., Ltd.
Appearance
Light pink oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202105302 · Approved 2021.07.12

This product's status changed to Approval withdrawn on 2023.09.14. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and prevention of cardiovascular disease (e.g., myocardial infarction and stroke)
Who uses it
Adults
Adult dosage
Take 1 tablet once daily with water. If possible, it is recommended that you take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and atorvastatin. Patients taking an amlodipine/valsartan combination and atorvastatin as separate medicines may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, a direct switch to the amlodipine/valsartan combination may be considered if blood pressure is not controlled with monotherapy using the individual components, as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. - Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. - Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. - Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Atorvastatin Patients should follow a standard cholesterol-lowering diet before and during treatment with atorvastatin. The medicine may be taken at any time of day, with or without food. 1. Dyslipidemia The recommended initial dose is atorvastatin 10 mg once daily. However, patients requiring a greater reduction in LDL cholesterol may start with 20 mg or 40 mg once daily (only when a reduction in LDL cholesterol of 45 % or more is required). This medicine is administered once daily at doses ranging from 10 ~ 80 mg. The initial and maintenance doses should be individualized according to the patient's characteristics, taking into account treatment goals and response. Lipid levels should be analyzed within 2 ~ 4 weeks after starting treatment and/or titrating the dose, and the dose should be adjusted accordingly. Because the goal of treatment is to lower LDL cholesterol, it is recommended that LDL cholesterol be used when initiating treatment and evaluating the response. However, if LDL cholesterol levels are unavailable, total cholesterol should be used to monitor the treatment response. Patients with homozygous familial hypercholesterolemia The dose is 10 ~ 80 mg once daily. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when such treatments are not available. - Patients with renal impairment: Renal disease does not affect the plasma concentration of atorvastatin or its LDL cholesterol-lowering effect; therefore, no dose adjustment is necessary. - Elderly patients: The efficacy and safety in patients aged 70 years or older are generally similar to those in the usual adult patient population.

Ingredients

Manufacturer
Aju Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and prevention of cardiovascular disease (e.g., myocardial infarction and stroke)

  • Essential hypertension
  • hypercholesterolemia
  • dyslipidemia
  • primary hypercholesterolemia
  • mixed dyslipidemia
  • primary Hyper beta-lipoproteinemia
  • elevated serum triglycerides
  • homozygous familial hypercholesterolemia
View approved original text

This medication is used for patients with chronic hypertension where blood pressure is not adequately controlled with monotherapy, using the combination of amlodipine and valsartan. Additionally, atorvastatin reduces the risk of myocardial infarction, stroke, and complications after vascular procedures in adults at high risk for cardiovascular disease and in patients with type 2 diabetes. Furthermore, it effectively reduces cholesterol and triglyceride levels in patients with dyslipidemia and plays a role in increasing good cholesterol (HDL) levels. This drug is very useful in managing hypertension and cardiovascular disease risks, as well as dyslipidemia simultaneously. Therefore, it is used to improve the health condition of patients with dyslipidemia accompanied by hypertension and cardiovascular disease risk.

Dosage and Administration

Adult dosage

Take 1 tablet once daily with water. If possible, it is recommended that you take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and atorvastatin. Patients taking an amlodipine/valsartan combination and atorvastatin as separate medicines may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, a direct switch to the amlodipine/valsartan combination may be considered if blood pressure is not controlled with monotherapy using the individual components, as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. - Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. - Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. - Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Atorvastatin Patients should follow a standard cholesterol-lowering diet before and during treatment with atorvastatin. The medicine may be taken at any time of day, with or without food. 1. Dyslipidemia The recommended initial dose is atorvastatin 10 mg once daily. However, patients requiring a greater reduction in LDL cholesterol may start with 20 mg or 40 mg once daily (only when a reduction in LDL cholesterol of 45 % or more is required). This medicine is administered once daily at doses ranging from 10 ~ 80 mg. The initial and maintenance doses should be individualized according to the patient's characteristics, taking into account treatment goals and response. Lipid levels should be analyzed within 2 ~ 4 weeks after starting treatment and/or titrating the dose, and the dose should be adjusted accordingly. Because the goal of treatment is to lower LDL cholesterol, it is recommended that LDL cholesterol be used when initiating treatment and evaluating the response. However, if LDL cholesterol levels are unavailable, total cholesterol should be used to monitor the treatment response. Patients with homozygous familial hypercholesterolemia The dose is 10 ~ 80 mg once daily. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when such treatments are not available. - Patients with renal impairment: Renal disease does not affect the plasma concentration of atorvastatin or its LDL cholesterol-lowering effect; therefore, no dose adjustment is necessary. - Elderly patients: The efficacy and safety in patients aged 70 years or older are generally similar to those in the usual adult patient population.

Precautions

This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. If there are muscle-related disorders or elevated muscle enzyme levels, the use of this medication should be stopped or done with caution as there is a risk of severe muscle damage affecting kidney function. Patients with allergies to any ingredients contained in this medication, those who are pregnant or breastfeeding, and patients with severe liver or kidney disease should not take it. In cases of certain health conditions such as hypotension, hypovolemia, hyperkalemia, renal artery stenosis, angioedema, heart failure, or myocardial infarction, this medication should be used cautiously under close supervision by healthcare professionals. While taking this medication, dizziness or fatigue may occur, so caution should be exercised while driving or operating machinery. Patients with impaired liver function should adjust the dosage and report any symptoms of liver dysfunction to their healthcare provider immediately. This medication can interact with other drugs, so it is essential to inform healthcare providers of other medications being taken, particularly specific antibiotics, antiviral agents, antacids, contraceptives, etc. Adverse reactions such as muscle pain, liver function abnormalities, and gastrointestinal issues may occur due to the atorvastatin component. If symptoms such as muscle pain, weakness, or fever arise, healthcare professionals should be informed immediately. This medication has not established safety and efficacy in children; therefore, it should not be administered to those under 18 years of age. Elderly patients may be more sensitive to this medication, so it is advisable to start with a lower dose and gradually increase it. Regular blood tests and kidney and liver function assessments should be conducted to ensure safety during treatment.

Side effects

  • Dry eyes
  • nausea
  • headache
  • nasopharyngitis
  • influenza
  • hypersensitivity
  • visual impairment
  • anxiety
  • dizziness
  • drowsiness
Show 184 more
  • positional dizziness
  • paresthesia
  • vertigo
  • tinnitus
  • tachycardia
  • palpitations
  • syncope
  • orthostatic hypotension
  • hypotension
  • cough
  • pharyngeal and laryngeal pain
  • diarrhea
  • abdominal pain
  • constipation
  • thirst
  • rash
  • erythema
  • sweating
  • itching
  • joint swelling
  • low back pain
  • arthritis
  • muscle spasm
  • weakness
  • pollakiuria
  • polyuria
  • erectile dysfunction
  • edema
  • localized edema
  • facial edema
  • peripheral edema
  • fatigue
  • flushing
  • asthenia
  • facial flushing
  • diplopia
  • thrombocytopenia
  • leukopenia
  • allergic reaction
  • hyperglycemia
  • insomnia
  • mood changes
  • tremors
  • taste abnormalities
  • peripheral neuropathy
  • hypertonia
  • arrhythmia
  • bradycardia
  • atrial fibrillation
  • ventricular tachycardia
  • myocardial infarction
  • vasculitis
  • angioedema
  • vesicular dermatitis
  • myalgia
  • renal failure
  • renal impairment
  • elevated serum creatinine
  • lethargy
  • malaise
  • chest pain
  • fatigue
  • fever
  • rhinitis
  • hyperglycemia
  • hypoglycemia
  • weight gain
  • anorexia
  • constipation
  • abdominal distension
  • dyspepsia
  • diarrhea
  • vomiting
  • belching
  • pharyngeal and laryngeal pain
  • nosebleed
  • nightmares
  • sensory abnormalities
  • amnesia
  • peripheral neuropathy
  • myalgia
  • arthralgia
  • limb pain
  • muscle cramps
  • joint swelling
  • back pain
  • neck pain
  • muscle fatigue
  • complications due to rupture
  • myopathy
  • myositis
  • rhabdomyolysis
  • tendon disorder
  • lupus-like syndrome
  • immune-mediated necrotizing myopathy
  • thrombocytopenia
  • allergic reaction
  • anaphylaxis
  • hepatitis
  • cholestasis
  • liver failure
  • blurred vision
  • tinnitus
  • hearing loss
  • urticaria
  • skin rash
  • hair loss
  • angioneurotic edema
  • erythema multiforme
  • mucocutaneous syndrome
  • gynecomastia
  • abnormal liver function tests
  • increased serum CK
  • positive urinary leukocytes
  • chest discomfort
  • abdominal discomfort
  • gastroesophageal reflux disease
  • neck pain
  • hypercholesterolemia
  • hypoglycemia
  • nocturia
  • Stevens-Johnson syndrome
  • thrombocytopenia
  • thrombocytopenia
  • leukopenia
  • anemia
  • decreased testosterone
  • elevation of cholinesterase
  • elevated TSH
  • elevated ACTH
  • decreased aldosterone
  • gynecomastia
  • elevated potassium
  • elevated BUN
  • cerebral infarction
  • palpitations
  • tachycardia
  • malaise
  • vasomotor edema
  • chest pain
  • angina
  • facial edema
  • fever
  • neck stiffness
  • generalized edema
  • amblyopia
  • dry eyes
  • refractive errors
  • ocular hemorrhage
  • hearing loss
  • glaucoma
  • pigment dispersion
  • taste loss
  • taste disorder
  • thrombocytopenia
  • leukopenia
  • anemia
  • sleep disturbances
  • amnesia
  • depression
  • interstitial lung disease
  • sexual dysfunction
  • hypoglycemia
  • hyperglycemia
  • anorexia
  • increased appetite
  • malaise
  • vasomotor edema
  • chest pain
  • angina
  • facial edema
  • fever
  • neck stiffness
  • generalized edema
  • chest pain
  • weight gain
  • arthralgia
  • skeletal pain
  • rhabdomyolysis
  • gingival hyperplasia
  • gastritis
  • neuroexcitability
  • sensory impairment
  • Stevens-Johnson syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is recommended to maintain the storage temperature between 1 degree and 30 degrees at room temperature.

Appearance and packaging

Appearance

Light pink oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.